Spanish Red Biotech Pipeline

Minoryx

MIN-102 (leriglitazone)

Type: Biodrugs/ Drugs
Therapeutic area: Cancer
Indication: Chronic X-linked Adrenoleukodystrophy (AMN; Adrenomyeloneuropathy)
Phase: 4Registration, 3Phase III, 2Phase II, 1Phase I, 2Regulatory Preclinical, 1Non Regulatory Preclinical